LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (Nasdaq: FOLD) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Amicus shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
The investigation is centered on whether Amicus and some of its officers and/or directors have committed violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Amicus announced post-market on November 28, 2016 that its oral drug Galafold (migalastat), used to treat Fabry disease, failed to meet the U.S. Food and Drug Administration's criteria for an expedited review, and that approval for the drug will be delayed until at least 2020. The Company expects to start clinical trials by next year, and trial data is expected to be available by 2019.
On this news, Amicus stock fell $1.81, or 21.75%, to close at $6.51 on November 29, 2016, causing investors serious harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.